Association of eIF3 p170 expression with chemotherapy response of lung cancer and its effects on cisplatin sensitivity in lung carcinoma cells

Abstract

The clinical data of 40 patients (males:females, 2.08:1) with peripheral primitive euroectodermal tumors (PNET) from 1997 to 2007 at Cancer Center, Sun Yat-Sen University were reviewed, without any selection according to primary tumor site or disease extension. The age at diagnosis ranged from 2 to 72 years (median, 18 years). Primary sites were chest (n ¼7), pelvis (n ¼ 8), retroperitoneum or abdomen (n ¼ 7), limbs (n ¼ 7), head and neck (n ¼ 6), and vertebral canal (n ¼ 5). At diagnosis, local extension was present in 7 patients, 5 patients had lymph node metastases, and 14 patients had distant metastases. Tumor size was greater than 10cm in 16 patients (40 %). There were 40 patients, 23 received multimodality treatment, 14 received only surgery or chemotherapy, 3 did not have any anticancer therapy. The median survival time was 23 months. The 1-, 2-, and 5-year overall survival (OS) rates of the 40 patients were 67.7 %, 49.9 % and 41.6 % respectively. Five-year OS was 57.9 % in patients received multimodality treatment, 13.1 % for the rest (P ¼ 0.000), 25.1 % in those with tumor size 10cm, 48.5 % in those with tumor size < 10cm (P¼0.028), 50.8 % in those received complete resection, 41.7% in those underwent incomplete resection, 27.5 % in those received no surgery (P < 0.05), 45.9 % in those with nonmetastasis, and 35.7 % in those with metastasis (P < 0.5). Based on our experience and a review of the literature, we concluded that multimodality treatment was the main treatment of peripheral primitive euroectodermal tumors. Tumor size greater than 10cm, complete resection, and metastasis are prognostic factors for survival.